SCHEMBL22725519

SCHEMBL22725519

CC(C)c1nccc(CC(C)c2cncc(CC(C)c3cccnn3)n2)n1

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21926453 0.85 CYP1A2 (0.31) —
SCHEMBL22725514 0.81 — —
SCHEMBL18910654 0.76 HRH4 (0.32) —
SCHEMBL21653566 0.75 SMN1; SMN2 (0.33) —
SCHEMBL23661913 0.75 CXCR4 (0.34) —
SCHEMBL22725661 0.74 TSHR (0.38) —
SCHEMBL22333290 0.73 — —
SCHEMBL29332959 0.71 ALDH1A1 (0.31) —
SCHEMBL25003875 0.71 TSHR (0.41) —
SCHEMBL22255144 0.70 AAK1 (0.33) —

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11091462-B2 (Hetero)arylamide compound for inhibiting protein kinase activity SHENZHEN TARGETRX, INC. (CN) 2021-08-17 — — US disclosed
US-20200377473-A9 (HETERO)ARYLAMIDE COMPOUND FOR INHIBITING PROTEIN KINASE ACTIVITY SHENZHEN TARGETRX, INC. (CN) 2020-12-03 — — US disclosed
Send feedback